论文部分内容阅读
2016年4月13号召开的国务院常务会议通过了《国务院关于修改〈疫苗流通和预防接种管理条例〉的决定》,药品批发企业经营疫苗将不被允许。自费接种的二类疫苗也将和一类疫苗一样,全部纳入省级公共资源交易平台集中采购。“集中采购”这一规制措施确实具有其合法性和合理性,在完善事前监管、安抚社会等方面都具有极大的作用。但仍具有一定缺陷。首先,“集中采购”的救济存在民事诉讼与行政诉讼的交叉性,只有将其缕清才能对受种者做全方位的权利保护。其次,二类疫苗缺乏强有力的问责机制,最后,二类疫苗由于“自费”的特点与“集中采购”的规制之间存在一定矛盾,需要找到两者的平衡点。本文在第三部分对应二类疫苗“集中采购”这一规制措施提出几点完善建议,以期真正实现“权利本位”的内在要求。
The State Council executive meeting on April 13, 2016 passed the Decision of the State Council on Amending the Regulations on the Management of Circulation and Vaccination of Vaccines, and the operation of vaccines for pharmaceutical wholesalers will not be allowed. Vaccine vaccination at its own second-category vaccine will also be the same as a class, all included in the provincial public resources trading platform for centralized procurement. “Centralized procurement ” This regulation does have its legitimacy and rationality, in improving the supervision in advance, to appease the community and so has a tremendous role. But still has some defects. First of all, the “centralized procurement ” remedy exists in the cross of civil litigation and administrative litigation, and only through its clearance can the species be protected by all-round rights. Second, there is a lack of a strong accountability mechanism for the two types of vaccines. Finally, there is a certain contradiction between the two types of vaccines due to the characteristics of “self-financing ” and “centralized procurement ”, and the balance between the two needs to be found. In the third part, this article puts forward some suggestions to improve the regulatory measures of the second category vaccines “centralized procurement ”, in order to realize the intrinsic requirement of “right standard ”.